UroGen Pharma Ltd Dividends
The next dividend date for UroGen Pharma Ltd has not yet been scheduled.
What is a Dividend Date
When we talk about a dividend date, we’re referring specifically to the ex-dividend date.
This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.
The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.
Most brokerages will automatically credit the dividend to your account once it’s issued.
Historical Dividends for UroGen Pharma Ltd (URGN)
More About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Owning UroGen Pharma Ltd Stock on the Dividend Date
If you own UroGen Pharma Ltd stock on the ex-dividend date, then you earn the associated dividend.
Theoretically, the price of UroGen Pharma Ltd stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of UroGen Pharma Ltd stock).
Therefore, it is typically not expected that there is any incremental profit to be gained from buying UroGen Pharma Ltd stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the UroGen Pharma Ltd dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.
Learning More UroGen Pharma Ltd Dividends
You can contact us any time if you would like to ask questions about UroGen Pharma Ltd dividends or anything else related to the stock market.